Cambridge Healthtech Institute’s 5th Annual

Gene Therapy Manufacturing

Scaling up and Supplying Vector-Based Gene Therapies

August 27-28, 2020


Cambridge Healthtech Institute’s Gene Therapy Manufacturing meeting tackles the practical challenges facing the process development, scale-up and production of viral vector-based gene therapies, tackling key topics such as AAV, lentivirus, and retrovirus upstream and downstream process development, scale-up, viral clearance, and viral vector supply for clinical and commercial manufacturing.

Preliminary Agenda


rAAV Vector Design, Capsid Directed Evolution and Scale-Up Activities Using the BEVS System

Jacek Lubelski, PhD, Vice President, Global Pharmaceutical Development, uniQure

Keeping High-Quality Vector in Economical Non-GMP Large-Scale Production

Sylvain Cecchini, PhD, Core Director, Associate Professor, Microbiology and Physiological Systems, UMass Medical School

FEATURED PRESENTATION: Novel Formulation Technologies for Gene Therapies

Maria A. Croyle, RPh, PhD, Glaxo Wellcome Endowed Professor of Pharmaceutics, Faculty Advisor, Rho Chi Honor Society, Nu Chapter, Department of Molecular Pharmaceutics and Drug Delivery, The University of Texas at Austin

Leveraging Multiple Production Platforms to Support AAV Drug Substance Production

Terrence Dobrowsky, PhD, Principal Engineer, Gene Therapy, Biogen

Cell Culture Manufacturing Platform Development for Recombinant AAV Production

Nitin Agarwal, PhD, Principal Scientist, Cell Culture & Fermentation Sciences, AstraZeneca

Development of a Next-Generation AAV Manufacturing Platform

Mike Delahaye, PhD, Lead, Industrialization, Cell Catapult

High-Yield Production Platform for Preclinical and Clinical rAAV

Nathalie Clément, PhD, Associate Director and Associate Professor, Powell Gene Therapy Center, Pediatrics, University of Florida

Engineering Strategies to Improve Yield

Sergei Zolotukhin, PhD, Professor, University of Florida

DSP Strategies for AAV Viral Vectors

Stephen Soltys, PhD, Director, Process Development, Avexis

Virus-Like Particles and Other Extracellular Particles from Insect and Mammalian Cells

Alois Jungbauer, PhD, Professor, Institute of Biotechnology, University of Natural Resources and Life Sciences (BOKU)

For more details on the conference, please contact:
Daniel Barry
Senior Conference Director
Cambridge Healthtech Institute

Phone: (+1) 781-247-6266


For partnering and sponsorship information, please contact:

Companies A-K
Sherry Johnson
Senior Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-972-1359

Companies L-Z
Carolyn Cooke
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-972-5412

Premier Sponsors: